SUMMARY A trispanning orphan receptor (TOR) has been described in Schistosoma haematobium and S. mansoni. Here we report thecompletemolecularorganizationoftheS.mansoniTORgene,alsoknownasSmCRIT(complementC2receptorinhibitortrispanning). The SmTOR gene consists of 4 exons and 3 introns as shown by cloning the single exons from S. mansonigenomic DNA and the corresponding cDNA from the larval stage (cercaria) and the adult worm. The SmTOR ORFconsists of 1260 bp and is longer than previously reported, with a fourth trans-membrane domain (proposed new name:Tetraspanning Orphan Receptor) and with, however, an unchanged C2-binding domain on the extracellular domain 1(ed1). Thisdomain differs inS. japonicum. A protein atthe approximate expected molecular weight (55 kDa) was detectedinadultwormextractswithpolyclonalandmonoclonalantibodies,andwasfoundtobeexpressedonthetegumentalsurfaceof cercariae.Key words: CRIT, TOR, Schistosoma, complement regulation. INTRODUCTION Schistosomiasis is a parasitic infection also knownas bilharzia named after Theodor Bilharz who firstdescribed it (Ross et al. 2002). There are 5 speciesof schistosoma that are known to infect humans bycontact with its larval stage, the cercariae: Schisto-soma mekongi, S. intercalatum, S. mansoni, S. japo-nicumandS.haematobium,thelatter3beingthemainschistosome species that affect humans (Hamburgeret al. 1998). Adult worm pairs reside in host veinsand produce eggs which penetrate the tissue. Theyend up excreted with feces where they complete theschistosoma life cycle by hatching and re-infectingfresh-water snails as intermediate hosts (Ross et al.2002). Between the mid-1990s and 2003 the esti-mated number of people at risk from schistosomiasisincreased from 702 million to 779 million and theestimated number of individuals infected increasedfrom 193 million to 207 million (Steinmann et al.2006). The treatment of choice is the chemothera-peutic agent praziquantel. However, drug treatmentalone might not be sufficient and a vaccine-linkedchemotherapy to control schisotomiasis is recom-mended (Bergquist et al. 2005). Naturally acquiredimmunity or vaccination in animals strongly dimin-ishes the pathology associated with schistosome in-fection.Thereareeffortstodevelopavaccineagainstschistosomiasis. Radio-attenuated cercariae induceda high level of protection in animal models (Minardet al. 1978; Stek et al. 1981) and naturally resistantpopulation groups exist (Correa-Oliveira et al.1989, 2000), which suggests that development of aneffective vaccine is likely to be possible (McManusand Loukas, 2008). There is a list of recombinantproteins that correlate with resistance in humanstudies and/or have shown efficacy in animal models(McManus and Loukas, 2008). Among these pro-mising vaccine candidates are the tetraspanins,SmTSP-1 and SmTSP-2, that are both recognizedby IgG1 and IgG3 from putatively resistant indi-viduals,SmTSP-2providinghighlevelofprotectionin the mouse vaccination model in addition (Tranet al. 2006). Another candidate, Fatty Acid-BindingProtein (FABP)-Sm14 is at the stage of plannedclinicaltrialsafterscale-upandindustrialproductionprocesses have been put in place (Tendler andSimpson, 2008).The host complement system participates in thefirst line of immune defences against the invadingparasite. Of the 3 pathways of complement acti-vation, the alternative pathway was shown to attackschistosomula(Ruppeletal.1984;Pearceetal.1990)and S. mansoni adult worms (Linder and Huldt,1983; Rasmussen and Kemp, 1987). Schistosomesare sensitive to killing by complement, but losetheir sensitivity with loss of the glycocalyx andmaturation. Partial tryptic digestion of adult wormtegumental proteins rendered them sensitive tocomplement attack as shown for S. mansoni byFishelson’s group (Marikovsky et al. 1990). The
Read full abstract